Quotes 5-day view Delayed Nasdaq
02/23/2021
02/24/2021
02/25/2021
02/26/2021
03/01/2021
Date
150.17(c)
144.79(c)
148.38(c)
154.81(c)
147.35
Last
15 509 168
9 757 204
15 172 131
13 445 239
4 222 947
Volume
-5.77%
-3.58%
+2.48%
+4.33%
-4.82%
Change
Sales 2021
16 474 M
-
-
Net income 2021
8 798 M
-
-
Net cash position 2021
13 038 M
-
-
P/E ratio 2021
7,12x
Yield 2021
-
Sales 2022
13 137 M
-
-
Net income 2022
5 654 M
-
-
Net cash position 2022
18 931 M
-
-
P/E ratio 2022
11,2x
Yield 2022
-
Capitalization
61 888 M
61 888 M
-
EV / Sales 2021
2,97x
EV / Sales 2022
3,27x
Nbr of Employees
1 300
Free-Float
90,0%
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:
- Collaboration revenue (79.8%);
- Grant revenue (20.2%).
At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and...
Notations Surperformance© of Moderna, Inc.
Trading Rating :
Investor Rating :
All news about MODERNA, INC.
News in other languages on MODERNA, INC.
Analyst Recommendations on MODERNA, INC.
MODERNA, INC. - 2020
The beginning of the move
BUY
Wall Street ends sharply lower, tech selloff weighs as bond yields climb
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MODERNA, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
16
Average target price
167,50 $
Last Close Price
154,81 $
Spread / Highest target
34,4%
Spread / Average Target
8,20%
Spread / Lowest Target
-48,3%
Please enable JavaScript in your browser's settings to use dynamic charts.